株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳卒中:パイプライン分析

Stroke - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229744
出版日 ページ情報 英文 593 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
脳卒中:パイプライン分析 Stroke - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 593 Pages
概要

脳卒中とは、酸素不足のために脳細胞が突然死するという症状です。症状は突然かつ急速に生じ、短時間(通常は数分〜数時間)で終了します。最初のうちは、患者は体調が悪く感じ、顔面が蒼白となり、気分も非常に悪くなります。また、突然の頭痛に悩まされることもあります。突然に顔面や手足、特に身体の片側が痺れる場合もあります。ろれつが回らない、話された内容を理解できない、視力が低下する、歩いたりバランスを取るのが難しくなる、という症状が出ることもあります。さらには、てんかんの発作が生じて気絶することもあります。

当レポートでは、世界各国での脳卒中治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

脳卒中の概要

治療薬の開発

  • 脳卒中向けパイプライン製品:概要
  • 脳卒中向けパイプライン製品:比較分析

各企業で開発中の脳卒中治療薬

大学/研究機関で研究中の脳卒中治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

脳卒中治療薬:開発中の製品の一覧(企業別)

脳卒中治療薬:研究中の製品の一覧(大学/研究機関別)

脳卒中治療薬の開発に従事している企業

  • AB Science SA
  • Acorda Therapeutics, Inc.
  • Acticor Biotech
  • ActiveSite Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • advanceCor GmbH
  • Affibody AB
  • Amarantus Bioscience Holdings, Inc.
  • Anavex Life Sciences Corp.
  • Angion Biomedica Corp.
  • Antoxis Limited
  • Aralez Pharmaceuticals Inc.
  • ArmaGen Inc.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bioasis Technologies Inc.
  • Biogen, Inc.
  • BioTime, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.他

脳卒中:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

脳卒中治療薬:パイプライン製品の最新動向

脳卒中治療薬:開発が休止状態の製品

脳卒中治療薬:開発が中止された製品

脳卒中関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7975IDB

Summary

Global Markets Direct's, 'Stroke - Pipeline Review, H1 2016', provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Stroke
  • The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects
  • The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Stroke

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Stroke
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Stroke Overview
  • Therapeutics Development
  • Stroke - Therapeutics under Development by Companies
  • Stroke - Therapeutics under Investigation by Universities/Institutes
  • Stroke - Pipeline Products Glance
  • Stroke - Products under Development by Companies
  • Stroke - Products under Investigation by Universities/Institutes
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Drug Profiles
  • Stroke - Recent Pipeline Updates
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Stroke, H1 2016
  • Number of Products under Development for Stroke - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Stroke - Pipeline by AB Science SA, H1 2016
  • Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Acticor Biotech, H1 2016
  • Stroke - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Stroke - Pipeline by advanceCor GmbH, H1 2016
  • Stroke - Pipeline by Affibody AB, H1 2016
  • Stroke - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Stroke - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Stroke - Pipeline by Angion Biomedica Corp., H1 2016
  • Stroke - Pipeline by Antoxis Limited, H1 2016
  • Stroke - Pipeline by Aralez Pharmaceuticals Inc., H1 2016
  • Stroke - Pipeline by ArmaGen Inc., H1 2016
  • Stroke - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Stroke - Pipeline by AstraZeneca Plc, H1 2016
  • Stroke - Pipeline by Athersys, Inc., H1 2016
  • Stroke - Pipeline by Bayer AG, H1 2016
  • Stroke - Pipeline by Bioasis Technologies Inc., H1 2016
  • Stroke - Pipeline by Biogen, Inc., H1 2016
  • Stroke - Pipeline by BioTime, Inc., H1 2016
  • Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016
  • Stroke - Pipeline by D-Pharm Ltd., H1 2016
  • Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Stroke - Pipeline by DiaMedica Inc., H1 2016
  • Stroke - Pipeline by Digna Biotech, S.L., H1 2016
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Stroke - Pipeline by Fina Biotech, H1 2016
  • Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Stroke - Pipeline by Glialogix, Inc., H1 2016
  • Stroke - Pipeline by Glucox Biotech AB, H1 2016
  • Stroke - Pipeline by Green Cross Corporation, H1 2016
  • Stroke - Pipeline by Grifols, S.A., H1 2016
  • Stroke - Pipeline by Huons Co., Ltd., H1 2016
  • Stroke - Pipeline by International Stem Cell Corporation, H1 2016
  • Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Stroke - Pipeline by JN-International Medical Corporation, H1 2016
  • Stroke - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Stroke - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Stroke - Pipeline by Living Cell Technologies Limited, H1 2016
  • Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016
  • Stroke - Pipeline by M et P Pharma AG, H1 2016
  • Stroke - Pipeline by Mapreg S.A.S., H1 2016
  • Stroke - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Stroke - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Stroke - Pipeline by Neuralstem, Inc., H1 2016
  • Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2016
  • Stroke - Pipeline by Neuronax SAS, H1 2016
  • Stroke - Pipeline by Neurotec Pharma SL, H1 2016
  • Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2016
  • Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by New World Laboratories, Inc., H1 2016
  • Stroke - Pipeline by NoNO, Inc., H1 2016
  • Stroke - Pipeline by Omeros Corporation, H1 2016
  • Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Pfizer Inc., H1 2016
  • Stroke - Pipeline by PharmatrophiX, Inc., H1 2016
  • Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2016
  • Stroke - Pipeline by Phylogica Limited, H1 2016
  • Stroke - Pipeline by PhytoHealth Corporation, H1 2016
  • Stroke - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Stroke - Pipeline by Primary Peptides, Inc., H1 2016
  • Stroke - Pipeline by Q Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by QR Pharma, Inc., H1 2016
  • Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by ReNeuron Group Plc, H1 2016
  • Stroke - Pipeline by SanBio, Inc., H1 2016
  • Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Stroke - Pipeline by StemCells, Inc., H1 2016
  • Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Stroke - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Stroke - Pipeline by SynZyme Technologies, LLC, H1 2016
  • Stroke - Pipeline by Targazyme, Inc., H1 2016
  • Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Stroke - Pipeline by TikoMed AB, H1 2016
  • Stroke - Pipeline by vasopharm GmbH, H1 2016
  • Stroke - Pipeline by Vicore Pharma AB, H1 2016
  • Stroke - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016
  • Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016
  • Stroke - Pipeline by Xigen SA, H1 2016
  • Stroke - Pipeline by Zocere, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Stroke Therapeutics - Recent Pipeline Updates, H1 2016
  • Stroke - Dormant Projects, H1 2016
  • Stroke - Dormant Projects (Contd..1), H1 2016
  • Stroke - Dormant Projects (Contd..2), H1 2016
  • Stroke - Dormant Projects (Contd..3), H1 2016
  • Stroke - Dormant Projects (Contd..4), H1 2016
  • Stroke - Dormant Projects (Contd..5), H1 2016
  • Stroke - Dormant Projects (Contd..6), H1 2016
  • Stroke - Dormant Projects (Contd..7), H1 2016
  • Stroke - Dormant Projects (Contd..8), H1 2016
  • Stroke - Dormant Projects (Contd..9), H1 2016
  • Stroke - Dormant Projects (Contd..10), H1 2016
  • Stroke - Dormant Projects (Contd..11), H1 2016
  • Stroke - Dormant Projects (Contd..12), H1 2016
  • Stroke - Dormant Projects (Contd..13), H1 2016
  • Stroke - Dormant Projects (Contd..14), H1 2016
  • Stroke - Discontinued Products, H1 2016
  • Stroke - Discontinued Products (Contd..1), H1 2016
  • Stroke - Discontinued Products (Contd..2), H1 2016
  • Stroke - Discontinued Products (Contd..3), H1 2016

List of Figures

  • Number of Products under Development for Stroke, H1 2016
  • Number of Products under Development for Stroke - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top